Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... Md., Aug. 14 Martek Biosciences,Corporation announced that it ... fiscal 2007 on September 5, 2007, at approximately 4:00 ... p.m. EDT Martek,will hold a conference call to discuss ... investors. The call is expected to be approximately one,hour ...
... 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: DRP) ... 2007. Highlights of the Second Quarter, 2007, - ... the same period of 2006, and ... quarter 2007;, - Gross profit and gross ...
... 15 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated ... AG (Wedel, Germany), its European partner,for the ... has recruited the 40th and final patient ...
Cached Biology Technology:Martek to Announce Third Quarter 2007 Results on September 5, 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 2ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 4
(Date:7/22/2014)... UT Arlington computer science and engineering professor with an ... three-year National Science Foundation grant worth more than $600,000 ... the fruit fly., Heng Huang, an associate professor, will ... the UT Arlington Computer Science and Engineering department. Scientists ... because a large number of genes involved in fruit ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... Researchers from the USC Schaeffer Center for Health ... governing antipsychotic drugs with increased incarceration rates for ... scrutiny over whether cutbacks in mental health actually ... account. , Some health plans require an extra ... ordered for patients. This step called prior ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... F. Harrington Professor Emeritus at the University of Delaware, ... Heck, 79, was honored alongside fellow researchers Akira Suzuki, ... Negishi, 75, of Purdue University, "for palladium-catalyzed cross couplings ... award. The Nobel Prize in Chemistry was announced ...
... National Science Foundation (NSF) grant to upgrade and expand ... Solar Array (OVSA) http://www.ovsa.njit.edu/ has been ... to help scientists better understand the nature of solar ... "Space weather incidents such as coronal mass ...
... State University finds that fish located near coal-fired power plants ... further away. The surprising finding appears to be linked to ... which unfortunately poses problems of its own. "We found ... from a coal-fired power plant had mercury levels more than ...
Cached Biology News:UD Professor Emeritus wins Nobel Prize in Chemistry 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Study: Fish near coal-fired power plants have lower levels of mercury 2
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: